Please try another search
Lifecore Biomedical, Inc. reported earnings results for the full year ended May 28, 2023. For the full year, the company reported net loss was USD 102.19 million compared to USD 112.87 million a year ago. Basic loss per share from continuing operations was USD 2.3 compared to USD 0.41 a year ago. Diluted loss per share from continuing operations was USD 2.3 compared to USD 0.41 a year ago. Basic loss per share was USD 3.41 compared to USD 3.84 a year ago. Diluted loss per share was USD 3.41 compared to USD 3.84 a year ago.
Period Ending: | May 28, 2023 | Feb 26, 2023 | Nov 27, 2022 | Aug 28, 2022 |
---|---|---|---|---|
Total Revenue | 25.52 | 27.6 | 38.8 | 43.36 |
Gross Profit | 8.42 | 5.98 | 7.11 | 6.25 |
Operating Income | -1.96 | -6.96 | -5.78 | -6.46 |
Net Income | -35.57 | -40.19 | -12.45 | -11.35 |
Period Ending: | May 28, 2023 | Feb 26, 2023 | Nov 27, 2022 | Aug 28, 2022 |
---|---|---|---|---|
Total Assets | 253.54 | 236.15 | 279.07 | 269.1 |
Total Liabilities | 218.46 | 163.44 | 204.91 | 188.73 |
Total Equity | 35.09 | 72.72 | 74.17 | 80.36 |
Period Ending: | May 28, 2023 | Feb 26, 2023 | Nov 27, 2022 | Aug 28, 2022 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | -0.272 | -2.95 | -1.53 | |
Cash From Investing Activities | -8.16 | -3.25 | 0.206 | |
Cash From Financing Activities | 24.57 | 8.81 | 3.91 | |
Net Change in Cash | 16.14 | 2.61 | 2.58 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review